妊娠相关性乳腺癌合并多种并发症一例报告
A Case Report of Pregnancy-Associated Breast Cancer Complicated with Multiple Comorbidities
摘要: 本文报道1例36岁G1P0孕37 + 5周女性患者,既往有脊髓灰质炎后遗症及营养不良史,因左乳巨大实性肿物伴腋窝淋巴结肿大半天入院,同时合并右肾重度积水、中度贫血。经多学科会诊评估,行剖宫产术后即刻乳腺穿刺活检,病理确诊为III级浸润性导管癌(Luminal B型)。患者基础状况差,术后予卵巢功能抑制剂联合选择性雌激素受体调节剂内分泌治疗。出院后失访,仅电话随访自述左乳肿块略缩小、疼痛可耐受,肿瘤疗效及手术可切除性有待进一步评估。合并严重基础疾病与多系统受累的妊娠期相关乳腺癌,采用个体化多学科协作诊疗,是保障母婴安全、改善预后的关键,可为复杂妊娠合并恶性肿瘤的临床处置提供参考。
Abstract: This paper reports a 36-year-old G1P0 female patient at 37 + 5 weeks of gestation, with a history of poliomyelitis sequelae and malnutrition. She was admitted due to a huge solid mass in the left breast with axillary lymphadenopathy for half a day, accompanied by severe right hydronephrosis and moderate anemia. After multidisciplinary team (MDT) evaluation, cesarean section was performed followed by immediate breast core-needle biopsy. Pathology confirmed grade III invasive ductal carcinoma (Luminal B type). Given her poor general condition, the patient received endocrine therapy combining ovarian function suppression (OFS) with a selective estrogen receptor modulator (SERM) postoperatively. She was lost to follow-up after discharge, and only telephone follow-up revealed a slight reduction in the left breast mass and tolerable pain. Antitumor efficacy and resectability require further evaluation. For pregnancy-associated breast cancer (PABC) complicated by severe comorbidities and multi-system involvement, individualized MDT management is crucial to ensure maternal-infant safety and improve prognosis, providing a reference for the clinical management of complex pregnancy with malignant tumors.
文章引用:肖莹莹, 况雪芊, 李玥涵, 刘海智. 妊娠相关性乳腺癌合并多种并发症一例报告[J]. 临床医学进展, 2026, 16(3): 1000-1007. https://doi.org/10.12677/acm.2026.163873

参考文献

[1] Amant, F., Loibl, S., Neven, P., et al. (2012) Breast Cancer in Pregnancy. The Lancet, 379, 570-579. [Google Scholar] [CrossRef
[2] Akhlaqi, M., Ghofrani, A., Najdi, N., et al. (2025) A Systematic Review and Meta-Analysis of Pregnancy-Associated Breast Cancer Incidence Rate. BMC Cancer, 25, Article No. 660. [Google Scholar] [CrossRef] [PubMed]
[3] Al-Amri, A.M. (2015) Clinical Presentation and Causes of the Delayed Diagnosis of Breast Cancer in Patients with Pregnancy Associated Breast Cancer. Journal of Family and Community Medicine, 22, 96-100. [Google Scholar] [CrossRef] [PubMed]
[4] 王宪尧. 中晚期妊娠肾窦分离的超声观察[J]. 实用妇科与产科杂志, 1992(2): 24.
[5] Andreoiu, M. and MacMahon, R. (2009) Renal Colic in Pregnancy: Lithiasis or Physiological Hydronephrosis? Urology, 74, 757-761. [Google Scholar] [CrossRef] [PubMed]
[6] 中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版) [J]. 中国癌症杂志, 2023, 33(12): 1092-1187.
[7] Bae, S.Y., Jung, S.P., Jung, E.S., et al. (2018) Clinical Characteristics and Prognosis of Pregnancy-Associated Breast Cancer: Poor Survival of Luminal B Subtype. Oncology, 95, 163-169. [Google Scholar] [CrossRef] [PubMed]
[8] 吴克瑾, 陈青, 刘荫华. 中国妊娠期与哺乳期乳腺癌临床实践指南(2022版) [J]. 中国实用外科杂志, 2022, 42(2): 146-150.
[9] Tsai, Y.L., Seow, K.M., Yieh, C.H., et al. (2007) Comparative Study of Conservative and Surgical Management for Symptomatic Moderate and Severe Hydronephrosis in Pregnancy: A Prospective Randomized Study. Acta Obstetricia et Gynecologica Scandinavica, 86, 1047-1050. [Google Scholar] [CrossRef] [PubMed]
[10] Margioula-Siarkou, G., Margioula-Siarkou, C., Petousis, S., et al. (2023) Breast Carcinogenesis during Pregnancy: Molecular Mechanisms, Maternal and Fetal Adverse Outcomes. Biology (Basel), 12, Article 408. [Google Scholar] [CrossRef] [PubMed]
[11] Lian, J. and Li, K. (2020) A Review of Breast Density Implications and Breast Cancer Screening. Clinical Breast Cancer, 20, 283-290. [Google Scholar] [CrossRef] [PubMed]
[12] Ruiz, R., Herrero, C., Strasser-Weippl, K., et al. (2017) Epidemiology and Pathophysiology of Pregnancy-Associated Breast Cancer: A Review. The Breast, 35, 136-141. [Google Scholar] [CrossRef] [PubMed]
[13] Lu, Y., Hajjar, A., Cryns, V.L., et al. (2022) Breast Cancer Risk for Women with Diabetes and the Impact of Metformin: A Meta-Analysis. Cancer Medicine, 12, 11703-11718. [Google Scholar] [CrossRef] [PubMed]
[14] Samuel, S.M., Varghese, E., Varghese, S., et al. (2018) Challenges and Perspectives in the Treatment of Diabetes Associated Breast Cancer. Cancer Treatment Reviews, 70, 98-111. [Google Scholar] [CrossRef] [PubMed]
[15] Garczorz, W., Kosowska, A. and Francuz, T. (2024) Antidiabetic Drugs in Breast Cancer Patients. Cancers (Basel), 16, Article No. 299. [Google Scholar] [CrossRef] [PubMed]
[16] 妊娠相关性乳腺癌临床诊治专家共识(2020版) [J]. 中华临床医师杂志(电子版), 2020, 14(5): 321-325.
[17] Macdonald, H.R. (2020) Pregnancy Associated Breast Cancer. The Breast Journal, 26, 81-85. [Google Scholar] [CrossRef] [PubMed]
[18] 陈青, 吴克瑾. 中国绝经前乳腺癌病人辅助内分泌治疗临床管理实践指南(2025版) [J]. 中国实用外科杂志, 2025, 45(5): 481-484+497.
[19] Zavialov, А.А., Tyryshkin, A.I. and Varlamova, S.E. (2023) Neoadjuvant Endocrine Therapy for Breast Cancer: State of the Art. Practical Oncology, 23, 395-405. [Google Scholar] [CrossRef
[20] Tan, Q.T., Alcantara, V.S., Sultana, R., et al. (2023) Pregnancy-Associated Breast Cancer: A Multicenter Study Comparing Clinicopathological Factors, Diagnosis and Treatment Outcomes with Non-Pregnant Patients. Breast Cancer Research and Treatment, 198, 53-66. [Google Scholar] [CrossRef] [PubMed]
[21] Chlebowski, R.T., Kim, J. and Haque, R. (2014) Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings. Cancer Prevention Research, 7, 378-387. [Google Scholar] [CrossRef
[22] Eliassen, F.M., Blåfjelldal, V., Helland, T., et al. (2023) Importance of Endocrine Treatment Adherence and Persistence in Breast Cancer Survivorship: A Systematic Review. BMC Cancer, 23, Article No. 625. [Google Scholar] [CrossRef] [PubMed]
[23] Bright, E.E., Finkelstein, L.B., Nealis, M.S., et al. (2023) A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence among Breast Cancer Survivors. Journal of Clinical Oncology, 41, 4548-4561. [Google Scholar] [CrossRef